CrossTORC and WNTegration in Disease: Focus on Lymphangioleiomyomatosis.
Jilly Frances EvansKseniya ObraztsovaSusan M LinVera P KrymskayaPublished in: International journal of molecular sciences (2021)
The mechanistic target of rapamycin (mTOR) and wingless-related integration site (Wnt) signal transduction networks are evolutionarily conserved mammalian growth and cellular development networks. Most cells express many of the proteins in both pathways, and this review will briefly describe only the key proteins and their intra- and extracellular crosstalk. These complex interactions will be discussed in relation to cancer development, drug resistance, and stem cell exhaustion. This review will also highlight the tumor-suppressive tuberous sclerosis complex (TSC) mutated, mTOR-hyperactive lung disease of women, lymphangioleiomyomatosis (LAM). We will summarize recent advances in the targeting of these pathways by monotherapy or combination therapy, as well as future potential treatments.
Keyphrases
- combination therapy
- stem cells
- cell proliferation
- papillary thyroid
- cell cycle arrest
- polycystic ovary syndrome
- squamous cell carcinoma
- current status
- type diabetes
- metabolic syndrome
- bone marrow
- pregnant women
- cancer therapy
- insulin resistance
- open label
- mesenchymal stem cells
- cell death
- pregnancy outcomes
- adipose tissue
- risk assessment
- study protocol
- pi k akt